‼️ 🇬🇧 AstraZeneca released full results from two successful late-stage trials of tozorakimab, an experimental therapy for chronic obstructive pulmonary disease (COPD), reinforcing expectations that it could become a breakthrough treatment and achieve peak annual sales exceeding $5 billion. The data showed the drug significantly reduced flare-ups across a broad range of patients, strengthening the case for its potential as a leading COPD therapy.
AlgoTrader 